Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Gavreto Second Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions

November 2020 – Lung Cancer

On September 4, 2020, the FDA accelerated the approval of Gavreto (pralsetinib; from Blueprint Medicines and Genentech), an oral RET inhibitor, for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC), the most common type of lung cancer, and RET fusions (genomic alterations), as detected by an FDA-approved test.

RET fusions and mutations are key causes in many types of cancer, including NSCLC and thyroid cancer. In May 2020, the FDA approved the first RET inhibitor Retevmo (selpercatinib) for patients with metastatic NSCLC and RET fusions or mutations (as well as for patients with metastatic thyroid cancer).

Gavreto is the second RET inhibitor approved by the FDA for patients with metastatic NSCLC and RET fusions or mutations. The FDA is also considering Gavreto as a potential treatment for metastatic thyroid cancer and RET fusions.

About 1% to 2% of people with NSCLC have RET fusions. Biomarker testing for RET fusions is the most effective way to identify people who are eligible for treatment with Gavreto.

“The FDA approval of Gavreto for RET fusion-positive non-small cell lung cancer is an important step towards our goal of providing an effective treatment option for every person diagnosed with lung cancer, no matter how rare or hard-to-treat their type of disease,” said Levi Garraway, MD, PhD, Chief Medical Officer and Head of Global Product Development at Genentech. “We remain committed to finding personalized treatment options for people with cancer based on specific genomic or molecular alterations.”

The FDA approved Gavreto for patients with NSCLC and RET fusions based on the results of the early-phase ARROW clinical trial, the first study that is evaluating the safety and efficacy of Gavreto in patients with NSCLC or thyroid cancer and RET fusions or mutations.

Among the 87 patients with NSCLC who have previously received chemotherapy, the overall response rate with Gavreto was 57%, which included some (5.7%) patients who had a complete response (no sign of cancer) to this treatment.

The average length of response has not been reached yet, meaning that in many of the patients, the tumor is still responding to treatment with Gavreto. In the 27 people in the study who had not received previous chemotherapy, the response rate was even better (70%), including 11% of patients who had a complete response to treatment.

The most common side effects with this targeted therapy were fatigue, constipation, musculoskeletal pain, and elevated blood pressure.

Blueprint Medicines is offering a patient support program—YourBlueprint program—to provide financial assistance for eligible patients who are prescribed Gavreto and have a hard time paying for this medication.

Recommended For You